128 related articles for article (PubMed ID: 2769234)
1. Antibody responses and protection in mice immunized with herpes simplex virus type 1 antigen immune-stimulating complex preparations.
Ertürk M; Jennings R; Hockley D; Potter CW
J Gen Virol; 1989 Aug; 70 ( Pt 8)():2149-55. PubMed ID: 2769234
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
3. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of HSV-1 antigens solubilised from infected cells by using non-ionic or zwitterionic detergents.
Jennings R; Erturk M
J Med Virol; 1990 Jun; 31(2):98-108. PubMed ID: 2167352
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
6. Characterization and immunogenicity of HSV-1 antigens obtained following zwitterionic detergent treatment.
Mukhlis FA; Jennings R; Stephenson TJ; Quasim T; Potter CW
Vaccine; 1986 Sep; 4(3):191-6. PubMed ID: 3020821
[TBL] [Abstract][Full Text] [Related]
7. Latent HSV-1 infection in mice immunized with a zwitterionic detergent-extracted HSV-1 antigen preparation.
al-Ghamdi A; Jennings R; Bentley H; Potter CW
Arch Virol; 1989; 108(1-2):19-31. PubMed ID: 2556982
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.
Ghazi HO; Erturk M; Stannard LM; Faulkner M; Potter CW; Jennings R
Arch Virol; 1995; 140(6):1015-31. PubMed ID: 7611875
[TBL] [Abstract][Full Text] [Related]
9. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
10. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems.
Hassan Y; Brewer JM; Alexander J; Jennings R
Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
13. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
[TBL] [Abstract][Full Text] [Related]
14. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
15. Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.
Erturk M; Hill TJ; Shimeld C; Jennings R
Arch Virol; 1992; 125(1-4):87-101. PubMed ID: 1642562
[TBL] [Abstract][Full Text] [Related]
16. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
[TBL] [Abstract][Full Text] [Related]
19. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice.
Durmanová V; Mosko T; Sapák M; Kosovský J; Rezuchová I; Buc M; Rajcáni J
Acta Microbiol Immunol Hung; 2006 Dec; 53(4):459-77. PubMed ID: 17278713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
